Symbols / GILD
GILD Chart
About
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 183.17B |
| Enterprise Value | 197.21B | Income | 8.51B | Sales | 29.44B |
| Book/sh | 18.23 | Cash/sh | 8.55 | Dividend Yield | 222.00% |
| Payout | 46.61% | Employees | — | IPO | — |
| P/E | 21.78 | Forward P/E | 15.28 | PEG | — |
| P/S | 6.22 | P/B | 8.10 | P/C | — |
| EV/EBITDA | 13.53 | EV/Sales | 6.70 | Quick Ratio | 1.31 |
| Current Ratio | 1.68 | Debt/Eq | 108.73 | LT Debt/Eq | — |
| EPS (ttm) | 6.78 | EPS next Y | 9.67 | EPS Growth | 23.50% |
| Revenue Growth | 4.70% | Earnings | 2026-04-23 | ROA | 12.52% |
| ROE | 40.66% | ROIC | — | Gross Margin | 78.84% |
| Oper. Margin | 37.40% | Profit Margin | 28.90% | Shs Outstand | 1.24B |
| Shs Float | 1.24B | Short Float | 1.91% | Short Ratio | 3.23 |
| Short Interest | — | 52W High | 157.29 | 52W Low | 93.37 |
| Beta | 0.39 | Avg Volume | 7.28M | Volume | 8.14M |
| Target Price | $156.59 | Recom | Buy | Prev Close | $149.83 |
| Price | $147.64 | Change | -1.46% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$156.59
Mean price target
2. Current target
$147.64
Latest analyst target
3. DCF / Fair value
$90.58
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$147.64
Low
$118.00
High
$177.00
Mean
$156.59
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | reit | Needham | Buy → Buy | $170 |
| 2026-02-20 | init | Barclays | — → Equal-Weight | $155 |
| 2026-02-11 | main | RBC Capital | Sector Perform → Sector Perform | $118 |
| 2026-02-11 | main | Truist Securities | Buy → Buy | $152 |
| 2026-02-11 | main | Wells Fargo | Overweight → Overweight | $165 |
| 2026-02-11 | main | Cantor Fitzgerald | Overweight → Overweight | $155 |
| 2026-02-11 | main | Scotiabank | Sector Outperform → Sector Outperform | $177 |
| 2026-02-11 | main | Needham | Buy → Buy | $170 |
| 2026-01-27 | main | Truist Securities | Buy → Buy | $145 |
| 2026-01-27 | main | Citigroup | Buy → Buy | $156 |
| 2026-01-26 | main | UBS | Buy → Buy | $155 |
| 2026-01-13 | main | Morgan Stanley | Overweight → Overweight | $150 |
| 2026-01-07 | main | Citigroup | Buy → Buy | $140 |
| 2025-12-12 | main | Morgan Stanley | Overweight → Overweight | $151 |
| 2025-12-10 | main | Wells Fargo | Overweight → Overweight | $150 |
| 2025-11-13 | main | Needham | Buy → Buy | $140 |
| 2025-11-13 | init | Scotiabank | — → Sector Outperform | $140 |
| 2025-11-03 | reit | Truist Securities | Buy → Buy | $145 |
| 2025-10-31 | main | Wells Fargo | Overweight → Overweight | $145 |
| 2025-10-31 | main | JP Morgan | Overweight → Overweight | $150 |
- GILD Stock Quote Price and Forecast - CNN Sun, 22 Feb 2026 08
- Gilead Sciences Stock Surged 50%, Here's Why - Trefis Wed, 04 Feb 2026 08
- Gilead execs hit TD Cowen, Leerink, Barclays in March webcasts - Stock Titan Mon, 23 Feb 2026 21
- Time To Take Profits On Gilead Sciences (Rating Downgrade) (NASDAQ:GILD) - Seeking Alpha Fri, 20 Feb 2026 19
- Argus Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat Fri, 20 Feb 2026 15
- Top bank revisits gold stock price target for rest of 2026 - thestreet.com Sun, 22 Feb 2026 15
- Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings? - Yahoo Finance hu, 05 Feb 2026 08
- Needham Reiterates Buy Rating for Gilead Sciences (GILD) with $1 - GuruFocus Mon, 23 Feb 2026 16
- Arcellx Stock (ACLX) Rockets on a Massive Deal with Gilead Sciences (GILD) - TipRanks Mon, 23 Feb 2026 17
- Why Gilead Sciences (GILD) Stock Is Up Today - Yahoo Finance Fri, 19 Dec 2025 08
- Lansforsakringar Fondforvaltning AB publ Grows Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat Sun, 22 Feb 2026 11
- Why Gilead Sciences (GILD) Outpaced the Stock Market Today - Yahoo Finance hu, 22 Jan 2026 08
- Johanna Mercier Sells 28,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat Wed, 18 Feb 2026 23
- Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline - Yahoo Finance Sat, 29 Nov 2025 08
- Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says - MarketBeat hu, 12 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 28000 | 4324228.0 | — | Sale at price 154.18 - 155.62 per share. | MERCIER JOHANNA | Officer | — | 2026-02-17 00:00:00 | D |
| 1 | 25000 | 1666000.0 | — | Conversion of Exercise of derivative security at price 66.64 per share. | MERCIER JOHANNA | Officer | — | 2026-02-17 00:00:00 | D |
| 2 | 3000 | 463290.0 | — | Sale at price 154.43 per share. | DICKINSON ANDREW D | Chief Financial Officer | — | 2026-02-17 00:00:00 | D |
| 3 | 115640 | 17346000.0 | — | Sale at price 150.00 per share. | O'DAY DANIEL PATRICK | Chief Executive Officer | — | 2026-02-05 00:00:00 | D |
| 4 | 115640 | 7633396.0 | — | Conversion of Exercise of derivative security at price 66.01 per share. | O'DAY DANIEL PATRICK | Chief Executive Officer | — | 2026-02-05 00:00:00 | D |
| 5 | 44867 | — | — | Stock Award(Grant) at price 0.00 per share. | MERCIER JOHANNA | Officer | — | 2026-02-03 00:00:00 | D |
| 6 | 131675 | — | — | Stock Award(Grant) at price 0.00 per share. | O'DAY DANIEL PATRICK | Chief Executive Officer | — | 2026-02-03 00:00:00 | D |
| 7 | 44867 | — | — | Stock Award(Grant) at price 0.00 per share. | DICKINSON ANDREW D | Chief Financial Officer | — | 2026-02-03 00:00:00 | D |
| 8 | 10000 | 1398911.0 | — | Sale at price 139.54 - 140.24 per share. | O'DAY DANIEL PATRICK | Chief Executive Officer | — | 2026-01-28 00:00:00 | D |
| 9 | 115640 | 15611400.0 | — | Sale at price 135.00 per share. | O'DAY DANIEL PATRICK | Chief Executive Officer | — | 2026-01-23 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -2.78B | -249.70M | -923.23M | -235.69M |
| TaxRateForCalcs | 0.30 | 0.18 | 0.21 | 0.25 |
| NormalizedEBITDA | 13.55B | 11.87B | 13.15B | 12.27B |
| TotalUnusualItems | -9.12B | -1.37B | -4.30B | -939.00M |
| TotalUnusualItemsExcludingGoodwill | -9.12B | -1.37B | -4.30B | -939.00M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 480.00M | 5.67B | 4.59B | 6.22B |
| ReconciledDepreciation | 2.77B | 2.69B | 2.10B | 2.05B |
| ReconciledCostOfRevenue | 6.25B | 6.50B | 5.66B | 6.60B |
| EBITDA | 4.43B | 10.50B | 8.85B | 11.33B |
| EBIT | 1.67B | 7.80B | 6.75B | 9.28B |
| NetInterestIncome | -696.00M | -568.00M | -829.00M | -1.00B |
| InterestExpense | 977.00M | 944.00M | 935.00M | 1.00B |
| InterestIncome | 281.00M | 376.00M | 106.00M | |
| NormalizedIncome | 6.82B | 6.79B | 7.97B | 6.93B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 480.00M | 5.67B | 4.59B | 6.22B |
| TotalExpenses | 18.25B | 18.31B | 16.31B | 16.45B |
| TotalOperatingIncomeAsReported | 1.66B | 7.61B | 7.33B | 9.92B |
| DilutedAverageShares | 1.25B | 1.26B | 1.26B | 1.26B |
| BasicAverageShares | 1.25B | 1.25B | 1.25B | 1.26B |
| DilutedEPS | 0.38 | 4.50 | 3.64 | 4.93 |
| BasicEPS | 0.38 | 4.54 | 3.66 | 4.96 |
| DilutedNIAvailtoComStockholders | 480.00M | 5.67B | 4.59B | 6.22B |
| NetIncomeCommonStockholders | 480.00M | 5.67B | 4.59B | 6.22B |
| NetIncome | 480.00M | 5.67B | 4.59B | 6.22B |
| MinorityInterests | 0.00 | 52.00M | 26.00M | 24.00M |
| NetIncomeIncludingNoncontrollingInterests | 480.00M | 5.61B | 4.57B | 6.20B |
| NetIncomeContinuousOperations | 479.00M | 5.61B | 4.57B | 6.20B |
| TaxProvision | 211.00M | 1.25B | 1.25B | 2.08B |
| PretaxIncome | 690.00M | 6.86B | 5.81B | 8.28B |
| OtherIncomeExpense | -9.12B | -1.38B | -4.33B | -1.58B |
| OtherNonOperatingIncomeExpenses | -2.00M | -11.00M | -29.00M | -639.00M |
| SpecialIncomeCharges | -8.84B | -1.21B | -3.64B | -939.00M |
| OtherSpecialCharges | 4.66B | 1.16B | 944.00M | 939.00M |
| WriteOff | 4.18B | 50.00M | 2.70B | 0.00 |
| GainOnSaleOfSecurity | -274.00M | -167.00M | -657.00M | |
| NetNonOperatingInterestIncomeExpense | -696.00M | -568.00M | -829.00M | -1.00B |
| InterestExpenseNonOperating | 977.00M | 944.00M | 935.00M | 1.00B |
| InterestIncomeNonOperating | 281.00M | 376.00M | 106.00M | |
| OperatingIncome | 10.51B | 8.81B | 10.97B | 10.86B |
| OperatingExpense | 12.00B | 11.81B | 10.65B | 9.85B |
| ResearchAndDevelopment | 5.91B | 5.72B | 4.98B | 4.60B |
| SellingGeneralAndAdministration | 6.09B | 6.09B | 5.67B | 5.25B |
| GrossProfit | 22.50B | 20.62B | 21.62B | 20.70B |
| CostOfRevenue | 6.25B | 6.50B | 5.66B | 6.60B |
| TotalRevenue | 28.75B | 27.12B | 27.28B | 27.30B |
| OperatingRevenue | 28.75B | 27.12B | 27.28B | 27.30B |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 1.25B | 1.25B | 1.25B | 1.25B |
| ShareIssued | 1.25B | 1.25B | 1.25B | 1.25B |
| NetDebt | 16.72B | 18.90B | 19.82B | 21.36B |
| TotalDebt | 26.71B | 24.99B | 25.23B | 26.70B |
| TangibleBookValue | -8.93B | -11.94B | -15.97B | -20.72B |
| InvestedCapital | 46.04B | 47.82B | 46.47B | 47.76B |
| WorkingCapital | 7.17B | 4.80B | 3.21B | 3.16B |
| NetTangibleAssets | -8.93B | -11.94B | -15.97B | -20.72B |
| CommonStockEquity | 19.33B | 22.83B | 21.24B | 21.07B |
| TotalCapitalization | 44.23B | 46.02B | 44.20B | 46.25B |
| TotalEquityGrossMinorityInterest | 19.25B | 22.75B | 21.21B | 21.06B |
| MinorityInterest | -84.00M | -84.00M | -31.00M | -5.00M |
| StockholdersEquity | 19.33B | 22.83B | 21.24B | 21.07B |
| GainsLossesNotAffectingRetainedEarnings | 132.00M | 28.00M | 2.00M | 83.00M |
| OtherEquityAdjustments | 132.00M | 28.00M | 2.00M | 83.00M |
| RetainedEarnings | 11.50B | 16.30B | 15.69B | 16.32B |
| AdditionalPaidInCapital | 7.70B | 6.50B | 5.55B | 4.66B |
| CapitalStock | 1.00M | 1.00M | 1.00M | 1.00M |
| CommonStock | 1.00M | 1.00M | 1.00M | 1.00M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 39.75B | 39.38B | 41.96B | 46.89B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 27.75B | 28.10B | 30.72B | 35.28B |
| OtherNonCurrentLiabilities | 1.29B | 1.28B | 1.18B | 976.00M |
| TradeandOtherPayablesNonCurrent | 830.00M | 2.04B | 3.92B | 4.77B |
| NonCurrentDeferredLiabilities | 724.00M | 1.59B | 2.67B | 4.36B |
| NonCurrentDeferredTaxesLiabilities | 724.00M | 1.59B | 2.67B | 4.36B |
| LongTermDebtAndCapitalLeaseObligation | 24.90B | 23.19B | 22.96B | 25.18B |
| LongTermDebt | 24.90B | 23.19B | 22.96B | 25.18B |
| CurrentLiabilities | 12.00B | 11.28B | 11.24B | 11.61B |
| OtherCurrentLiabilities | 2.27B | 2.33B | 2.18B | |
| CurrentDebtAndCapitalLeaseObligation | 1.81B | 1.80B | 2.27B | 1.52B |
| CurrentDebt | 1.81B | 1.80B | 2.27B | 1.52B |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.23B | 1.20B | 1.02B | 927.00M |
| CurrentProvisions | 321.00M | 387.00M | 422.00M | 499.00M |
| PayablesAndAccruedExpenses | 6.37B | 5.56B | 5.34B | 8.67B |
| CurrentAccruedExpenses | 3.89B | 3.80B | 3.48B | 7.42B |
| Payables | 2.48B | 1.76B | 1.86B | 1.24B |
| TotalTaxPayable | 1.65B | 1.21B | 959.00M | 539.00M |
| IncomeTaxPayable | 1.65B | 1.21B | 959.00M | 539.00M |
| AccountsPayable | 833.00M | 550.00M | 905.00M | 705.00M |
| TotalAssets | 58.99B | 62.12B | 63.17B | 67.95B |
| TotalNonCurrentAssets | 39.82B | 46.04B | 48.73B | 53.18B |
| OtherNonCurrentAssets | 6.15B | 4.79B | 4.80B | 4.96B |
| InvestmentsAndAdvances | 0.00 | 1.16B | 1.25B | 1.31B |
| InvestmentinFinancialAssets | 0.00 | 1.16B | 1.25B | 1.31B |
| AvailableForSaleSecurities | 1.16B | 1.25B | 1.31B | |
| GoodwillAndOtherIntangibleAssets | 28.26B | 34.77B | 37.21B | 41.79B |
| OtherIntangibleAssets | 19.95B | 26.45B | 28.89B | 33.45B |
| Goodwill | 8.31B | 8.31B | 8.31B | 8.33B |
| NetPPE | 5.41B | 5.32B | 5.47B | 5.12B |
| AccumulatedDepreciation | -2.47B | -2.45B | -2.19B | -1.89B |
| GrossPPE | 7.88B | 7.77B | 7.66B | 7.01B |
| ConstructionInProgress | 501.00M | 661.00M | 719.00M | 1.06B |
| OtherProperties | 1.19B | 1.15B | 1.11B | 952.00M |
| MachineryFurnitureEquipment | 1.09B | 1.07B | 880.00M | 807.00M |
| BuildingsAndImprovements | 4.54B | 4.33B | 4.39B | 3.79B |
| LandAndImprovements | 561.00M | 561.00M | 562.00M | 404.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 19.17B | 16.09B | 14.44B | 14.77B |
| OtherCurrentAssets | 995.00M | 2.37B | 1.77B | 2.14B |
| PrepaidAssets | 480.00M | 1.77B | 2.14B | |
| Inventory | 1.71B | 1.79B | 1.51B | 1.62B |
| Receivables | 4.42B | 4.66B | 4.78B | 4.49B |
| AccountsReceivable | 4.42B | 4.66B | 4.78B | 4.49B |
| AllowanceForDoubtfulAccountsReceivable | -900.00M | -836.00M | -687.00M | -785.00M |
| GrossAccountsReceivable | 5.32B | 5.50B | 5.46B | 5.28B |
| CashCashEquivalentsAndShortTermInvestments | 11.57B | 7.26B | 6.38B | 6.52B |
| OtherShortTermInvestments | 1.58B | 1.18B | 973.00M | 1.18B |
| CashAndCashEquivalents | 9.99B | 6.08B | 5.41B | 5.34B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 10.30B | 7.42B | 8.34B | 10.80B |
| RepurchaseOfCapitalStock | -1.15B | -1.00B | -1.40B | -546.00M |
| RepaymentOfDebt | -1.97B | -2.25B | -1.50B | -4.75B |
| IssuanceOfDebt | 3.46B | 1.98B | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 422.00M | 232.00M | 309.00M | 169.00M |
| CapitalExpenditure | -523.00M | -585.00M | -728.00M | -579.00M |
| InterestPaidSupplementalData | 951.00M | 891.00M | 907.00M | 979.00M |
| IncomeTaxPaidSupplementalData | 2.78B | 3.99B | 3.14B | 2.51B |
| EndCashPosition | 9.99B | 6.08B | 5.41B | 5.34B |
| BeginningCashPosition | 6.08B | 5.41B | 5.34B | 6.00B |
| EffectOfExchangeRateChanges | -40.00M | 57.00M | -63.00M | -35.00M |
| ChangesInCash | 3.95B | 616.00M | 137.00M | -624.00M |
| FinancingCashFlow | -3.43B | -5.12B | -6.47B | -8.88B |
| CashFlowFromContinuingFinancingActivities | -3.43B | -5.13B | -6.47B | -8.88B |
| NetOtherFinancingCharges | -281.00M | -278.00M | -173.00M | -145.00M |
| CashDividendsPaid | -3.92B | -3.81B | -3.71B | -3.60B |
| CommonStockDividendPaid | -3.92B | -3.81B | -3.71B | -3.60B |
| NetCommonStockIssuance | -728.00M | -768.00M | -1.09B | -377.00M |
| CommonStockPayments | -1.15B | -1.00B | -1.40B | -546.00M |
| CommonStockIssuance | 422.00M | 232.00M | 309.00M | 169.00M |
| NetIssuancePaymentsOfDebt | 1.49B | -270.00M | -1.50B | -4.75B |
| NetLongTermDebtIssuance | 1.49B | -270.00M | -1.50B | -4.75B |
| LongTermDebtPayments | -1.97B | -2.25B | -1.50B | -4.75B |
| LongTermDebtIssuance | 3.46B | 1.98B | 0.00 | 0.00 |
| InvestingCashFlow | -3.45B | -2.27B | -2.47B | -3.13B |
| CashFlowFromContinuingInvestingActivities | -3.45B | -2.27B | -2.47B | -3.13B |
| NetOtherInvestingChanges | 58.00M | -1.00M | 19.00M | |
| NetInvestmentPurchaseAndSale | 1.86B | -528.00M | 60.00M | -987.00M |
| SaleOfInvestment | 2.59B | 1.84B | 2.00B | 2.91B |
| PurchaseOfInvestment | -736.00M | -2.37B | -1.94B | -3.90B |
| NetBusinessPurchaseAndSale | -4.84B | -1.15B | -1.80B | -1.58B |
| PurchaseOfBusiness | -4.84B | -1.15B | -1.80B | -1.58B |
| CapitalExpenditureReported | -523.00M | -585.00M | -728.00M | -579.00M |
| OperatingCashFlow | 10.83B | 8.01B | 9.07B | 11.38B |
| CashFlowFromContinuingOperatingActivities | 10.83B | 8.01B | 9.07B | 11.38B |
| ChangeInWorkingCapital | -880.00M | -2.30B | -1.76B | 489.00M |
| ChangeInOtherWorkingCapital | -732.00M | -1.77B | -364.00M | -361.00M |
| ChangeInPayablesAndAccruedExpense | 398.00M | 111.00M | -549.00M | 571.00M |
| ChangeInAccruedExpense | 108.00M | 458.00M | -775.00M | 689.00M |
| ChangeInPayable | 290.00M | -347.00M | 226.00M | -118.00M |
| ChangeInAccountPayable | 290.00M | -347.00M | 226.00M | -118.00M |
| ChangeInTaxPayable | -568.00M | -364.00M | ||
| ChangeInIncomeTaxPayable | -568.00M | -364.00M | ||
| ChangeInPrepaidAssets | -259.00M | 39.00M | -134.00M | -45.00M |
| ChangeInInventory | -426.00M | -842.00M | -310.00M | 11.00M |
| ChangeInReceivables | 139.00M | 157.00M | -406.00M | 313.00M |
| ChangesInAccountReceivables | 139.00M | 157.00M | -406.00M | 313.00M |
| OtherNonCashItems | 5.02B | 1.98B | 1.72B | 1.51B |
| StockBasedCompensation | 835.00M | 766.00M | 637.00M | 635.00M |
| AssetImpairmentCharge | 4.18B | 50.00M | 2.70B | 0.00 |
| DeferredTax | -1.84B | -962.00M | -1.55B | -116.00M |
| DeferredIncomeTax | -1.84B | -962.00M | -1.55B | -116.00M |
| DepreciationAmortizationDepletion | 2.77B | 2.69B | 2.10B | 2.05B |
| DepreciationAndAmortization | 2.77B | 2.69B | 2.10B | 2.05B |
| AmortizationCashFlow | 2.39B | 2.34B | 1.78B | 1.72B |
| AmortizationOfIntangibles | 2.39B | 2.34B | 1.78B | 1.72B |
| Depreciation | 381.00M | 354.00M | 323.00M | 329.00M |
| OperatingGainsLosses | 274.00M | 167.00M | 657.00M | 610.00M |
| GainLossOnInvestmentSecurities | 274.00M | 167.00M | 657.00M | 610.00M |
| NetIncomeFromContinuingOperations | 480.00M | 5.61B | 4.57B | 6.20B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GILD
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|